Therapeutic RNAs are becoming one of the dominant modalities to treat disease in the near future. Yet, while the industry has made rapid strides in engineering RNA payloads to be more tolerable, effective and long-lasting, RNA delivery still relies on the first generation of lipid nanoparticle technology. Optimeos has developed a novel nanoparticle platform to deliver the potential of RNA and DNA medicines across the range of human disease through these key points of differentiation:

1) Tunable immunogenicity: Reduction of immune activation for protein replacement therapy applications via nanoparticles that do not require cationic lipids or cationic polymers; or enhanced immunogenicity  for vaccine applications through modular surface chemistry and/or co-encapsulation with adjuvants
2) Unmatched capability for multiple payload delivery: Co-encapsulation of numerous APIs such as mRNA, siRNA, tRNA, DNA, ASO, proteins, peptides, small molecules or adjuvants
3) Enhanced tissue targeting: Modular particle assembly allows addition of targeting moieties or unique polymers to direct  payload to different tissues
4) Superior dosing profile: Technology enables a 5x higher payload content for more efficient disease modification